Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for...
Sanuwave Announces Q2 FY2026 Financial Results ...
EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will...
Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results...
EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in...
Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance...
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn.,...
Sanuwave Health Updates Second Quarter 2026 Guidance...
Sanuwave Health (NASDAQ:SNWV) reported record first-quarter revenue and rising consumables utilization, while management said the advanced wound care market began to recover after a difficult start to...
Sanuwave Announces Revenues and Financial Results for Q1 FY2026 ...